Does overexpression of VEGFR and TIMP2 predict survival in primary cervical cancer (CC) patients? Results of a companion protocol of the randomized, phase III adjuvant trial of simultaneous cisplatin radiochemotherapy versus sequential carboplatin and paclitaxel followed by radiotherapy.

Christina Fotopoulou,Elena Ioana Braicu,Radoslav Chekerov,Rolf Richter,Monika Mentze,Klaus Pietzner,Carmen Pop,Oumar Camara,G. Oskay-Özcelik,Sherko Kuemmel,J.-U. Blohmer,Werner Lichtenegger,Jalid Sehouli,Toc Noggo

Does overexpression of VEGFR and TIMP2 predict survival in primary cervical cancer (CC) patients? Results of a companion protocol of the randomized, phase III adjuvant trial of simultaneous cisplatin radiochemotherapy versus sequential carboplatin and paclitaxel followed by radiotherapy.

2011

Christina Fotopoulou
Elena Ioana Braicu
Radoslav Chekerov
Rolf Richter
Monika Mentze
Klaus Pietzner
Carmen Pop
Oumar Camara
G. Oskay-Özcelik
Sherko Kuemmel
J.-U. Blohmer
Werner Lichtenegger
Jalid Sehouli
Toc Noggo

e15507 Background: Aim of the study was to analyse the expression-profile of IGF1, IGFBP3, sICAM1, sVCAM1, MMP2, MMP9, TIMP2, VEGF, VEGFD, VEGFC and VEGFR in patients with FIGO-stage high-risk Ib-I...

Keywords:

Companion Protocol
Carboplatin
Cisplatin
Paclitaxel
Adjuvant
Cervical cancer
VEGF receptors
Radiation therapy
Internal medicine
Oncology
Medicine
Vascular endothelial growth factor C
MMP2

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations